M

Madrigal Pharmaceuticals
D

MDGL

338.58
USD
12.41
(3.80%)
مغلق
حجم التداول
11,795
الربح لكل سهم
-11
العائد الربحي
-
P/E
-14
حجم السوق
7,384,567,602
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AGIO
    0.740
    (2.19%)
    34.480 USD
    ALNY
    ALNY
    3.65
    (1.33%)
    277.41 USD
    A
    ARWR
    0.265
    (1.33%)
    20.220 USD
    C
    CRBP
    0.28000
    (2.91%)
    9.91000 USD
    C
    CRSP
    0.860
    (2.09%)
    42.060 USD
    E
    EDIT
    0.03000
    (2.24%)
    1.37000 USD
    MRNA
    MRNA
    0.350
    (0.86%)
    41.060 USD
    N
    NTLA
    0.400
    (3.95%)
    10.520 USD
    V
    VKTX
    0.275
    (0.82%)
    33.670 USD
    المزيد
الأخبار
المقالات

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.